261 related articles for article (PubMed ID: 29883531)
21. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
22. Development and Characterization of a Wee1 Kinase Degrader.
Li Z; Pinch BJ; Olson CM; Donovan KA; Nowak RP; Mills CE; Scott DA; Doctor ZM; Eleuteri NA; Chung M; Sorger PK; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):57-65.e9. PubMed ID: 31735695
[TBL] [Abstract][Full Text] [Related]
23. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
24. Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
Yang L; Shen C; Pettit CJ; Li T; Hu AJ; Miller ED; Zhang J; Lin SH; Williams TM
Clin Cancer Res; 2020 Jul; 26(14):3740-3750. PubMed ID: 32220892
[TBL] [Abstract][Full Text] [Related]
25. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
26. Wee1 kinase as a target for cancer therapy.
Do K; Doroshow JH; Kummar S
Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
[TBL] [Abstract][Full Text] [Related]
27. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
28. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
[TBL] [Abstract][Full Text] [Related]
29. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination.
Krajewska M; Heijink AM; Bisselink YJ; Seinstra RI; Silljé HH; de Vries EG; van Vugt MA
Oncogene; 2013 Jun; 32(24):3001-8. PubMed ID: 22797065
[TBL] [Abstract][Full Text] [Related]
30. Ensemble docking-based virtual screening toward identifying inhibitors against Wee1 kinase.
Li Y; Wu DM; Kong LM; Zhang S; Du H; Sun W; Zhang L; Li Y; Zuo Z
Future Med Chem; 2019 Aug; 11(15):1889-1906. PubMed ID: 31517534
[No Abstract] [Full Text] [Related]
31. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
[TBL] [Abstract][Full Text] [Related]
32. WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells.
Moiseeva TN; Qian C; Sugitani N; Osmanbeyoglu HU; Bakkenist CJ
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):23891-23893. PubMed ID: 31712441
[TBL] [Abstract][Full Text] [Related]
33. Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs.
Indovina P; Giordano A
Cancer Biol Ther; 2010 Apr; 9(7):523-5. PubMed ID: 20150761
[No Abstract] [Full Text] [Related]
34. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer.
Takashima Y; Kikuchi E; Kikuchi J; Suzuki M; Kikuchi H; Maeda M; Shoji T; Furuta M; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J; Konno S
Int J Cancer; 2020 Feb; 146(4):1114-1124. PubMed ID: 31199520
[TBL] [Abstract][Full Text] [Related]
35. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.
de Gooijer MC; Buil LCM; Beijnen JH; van Tellingen O
Invest New Drugs; 2018 Jun; 36(3):380-387. PubMed ID: 29147815
[TBL] [Abstract][Full Text] [Related]
36. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
[TBL] [Abstract][Full Text] [Related]
38. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
[TBL] [Abstract][Full Text] [Related]
39. p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775.
Hauge S; Macurek L; Syljuåsen RG
Cell Cycle; 2019 Apr; 18(8):834-847. PubMed ID: 30943845
[TBL] [Abstract][Full Text] [Related]
40. Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation.
Wang B; Sun L; Yuan Z; Tao Z
Med Oncol; 2020 Jul; 37(8):66. PubMed ID: 32696094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
